Last updated: 08/07/2019 09:10:23

Assessment of the cosmetic benefit of a skin cream in healthy females with mild to advanced photo-damaged facial skin who have undergone a Glycolic Acid facial peel procedure

GSK study ID
206827
See study documents
Clinicaltrials.gov ID
NCT03197883
See results summary
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A randomized, evaluator-blind, single-center and two-arm clinical study designed to evaluate the local tolerance and cosmetic efficacy of a topical skin care formulation in healthy female subjects with mild to advanced photo-damaged facial skin who have undergone a 70% Glycolic Acid facial peel procedure
Trial description: To evaluate the local tolerance and cosmetic efficacy of a topical skin care formulation in healthy female participants with mild to advanced photo-damaged facial skin who have undergone a 70% Glycolic Acid facial peel procedure.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Evaluator Global Assessment Scores

Timeframe: 14 days after completion of the facial peel procedure

Secondary outcomes:

Change form baseline in total score of dermatologist assessments

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in Individual Dermatologist scores for erythema, edema, desquamation and dryness

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in sum of participant self-assessment scores for redness, pain, stinging/burning, itching, tightness and dryness

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in participant self-assessment scores for redness

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in participant self-assessment scores for pain

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in participant self-assessment scores for itching

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in participant self-assessment scores for stinging/burning

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in participant self-assessment scores for tightness

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in participant self-assessment scores for dryness

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in instrumental measurement of barrier function using Tewameter

Timeframe: 14 days after completion of the facial peel procedure

Change from baseline in instrumental measurement of moisturisation using Corneometer

Timeframe: 14 days after completion of the facial peel procedure

Global self-assessment of participants

Timeframe: 14 days after completion of the facial peel procedure

Interventions:
  • Other: Test Product
  • Other: Cleanser
  • Other: Sunscreen
    • Enrollment:
    123
    Primary completion date:
    2017-31-10
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Skin Care
    Product
    GI148917, sodium bicarbonate
    Collaborators
    Not applicable
    Study date(s)
    July 2017 to October 2017
    Type
    Interventional
    Phase
    Not applicable

    Participation criteria

    Sex
    Female
    Age
    30 - 60 years
    Accepts healthy volunteers
    Yes
    • Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
    • Females aged between 30 and 60 years inclusive.
    • Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
    • Women who are breast-feeding.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
    • Females aged between 30 and 60 years inclusive.
    • Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination.
    • Willingness to actively participate in the study and to attend all scheduled visits.
    • Skin Type: Fitzpatrick phototype II-IV and participants with Glogau photoaging type II-III
    • Females of childbearing potential who are, in the opinion of the investigator, practising a reliable method of contraception. Adequate contraception is defined as abstinence, oral contraceptive, either combined or progestogen alone or injectable progestogen or implants of levonorgestrel or estrogenic vaginal ring or percutaneous contraceptive patches or intrauterine device or intrauterine system or double barrier method (condom or occlusive cap [diaphragm or cervical vault caps] plus spermicidal agent [foam, gel, film, cream, suppository]) or male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant.
    Exclusion criteria:
    • Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
    • Women who are breast-feeding.
    • a) Active skin disease or open wound in the test area, b) Medical history of using a medicated acne treatment (e.g. Benzoyl Peroxide, Clindamycin, isotretinoin) within the last 24 months, c)Medical history of dysplastic nevi or melanoma, d) Preexisting inflammatory dermatoses such as psoriasis, atopic dermatitis, e) Moles, tattoos, scars, irritated skin, hairs, etc. at the test area that could, in the opinion of the investigator, influence the investigation, f) Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines within 7 days prior to screening and/or throughout the entire course of the study, g) Systemic use of over-the-counter (OTC) analgesics or anti-inflammatory drugs 24 hours prior to screening. h)Systemic use of any photosensitizing medication 2 weeks prior to screening, i) Intense sun exposure, UV-treatments or tanning salon visit within two weeks prior to screening, j) One of the following illnesses that might require regular systemic medication; Insulin-dependent diabetes, cancer, k) One of the following illnesses if not medicated: Asthma, hypertension, l) Medical history of abnormal response to sunlight, m) Participant's with a history of mental illness, n) Ocular surgery within the last 12 months. o) Ocular trauma, infection or inflammation within the last 3 months, p) Active blepharitis, conjunctivitis, uveitis, q) Any ocular pathology requiring topical ocular treatment within the last 1 month, r) Ocular laser within the last 3 months, s) Aesthetic, cosmetic or dermatological treatment in the treatment area (face), including the use of skin tone lightning products, within the last 3 months, t) Use of facial scrubs, depilatory creams, waxing and/or bleaching within the last 2 weeks prior to screening, u) Microdermabrasion and/or laser hair removal within the last 4 weeks prior to screening, v) Medical history of Herpes Simplex (Cold Sores).
    • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients and documented allergies to cosmetic products or study ingredients.
    • Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit and previous participation in this study.
    • Recent history (within the last 5 years) of alcohol or other substance abuse.
    • An employee of the sponsor or the study site or members of their immediate family.
    • Required to work outside during daylight hours over the duration of the study and required or otherwise intending to spend prolonged periods of time outside during daylight hours over the duration of the study (e.g. holiday, sunbathing, and gardening).
    • A score of “Severe” for any Dermatologist or Participant's Self-Assessed endpoint at any time for the study material sensitivity test.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Campinas, São Paulo, Brazil, 13084-791
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2017-31-10
    Actual study completion date
    2017-31-10

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Review and Approval was conducted on previous disclosure system and therefore, the document was uploaded directly to the PRS system.
    Click here
    Review and Approval was conducted on previous disclosure system and therefore, the document was uploaded directly to the PRS system.
    Click here
    Access to clinical trial data by researchers
    Visit website